← Home · All topics

Precivityad2

2 GoKawiil briefs on this topic

FDA Clears PrecivityAD2 Blood Test for Alzheimer's in Adults as Young as 40

The FDA has approved PrecivityAD2, a blood test that detects amyloid and tau biomarkers linked to Alzheimer's disease in symptomatic patients starting at age 40. In a validation study of 1,142 adults, the test correctly identified positive biomarkers 97.6% of the time, even among patients with conditions like kidney disease or diabetes that can otherwise skew results.

science.slashdot.org · 2026-08-24

FDA clears WashU-derived PrecivityAD2 blood test for Alzheimer's diagnosis

The FDA has cleared PrecivityAD2, a blood test built on technology from Washington University School of Medicine, to help identify amyloid plaques linked to Alzheimer's disease. Developed by WashU spinoff C2N Diagnostics, the test uses high-resolution mass spectrometry to quantify biomarkers with over 90% accuracy, offering a less invasive option than spinal taps or brain imaging.

medicine.washu.edu · 2026-08-24